Abstract
AbstractAntigens expressed on the surface of cancer cells are accessible targets for both humoral and cell-mediated immune responses, and are therefore potential candidates for vaccine development. Treating surface of live human breast adenocarcinoma cells (MCF-7) with trypsin yields a digest that contains 0.7% of total cell protein. Despite this difference, the trypsin digest stimulates in cytotoxicity assays anti-tumor response which kills 10-40% more cancer cells than those stimulated with cells themselves. From these results, we concluded that trypsin digest obtained from live cancer cells contains the essential antigens to induce an immune-mediated anti-tumor effect, and therefore, is candidate for anti-tumor vaccine development.
Highlights
Vaccines which use cancer cells as a source of these antigens have been investigated for more than 20 years, and cell-based vaccinations show great potential for prevention different types of cancers [1]
While cancer cells provide surface antigens that are targets for a desired immune response, they contain a high abundance of house-keeping proteins, carbohydrates, nucleic acids, and other intracellular contents that are ubiquitous in mammalian cells
Protein concentration was measured in MCF-7 lysate and in trypsin digest obtained from the same quantity of cancer cells
Summary
Vaccines which use cancer cells as a source of these antigens have been investigated for more than 20 years, and cell-based vaccinations show great potential for prevention different types of cancers [1]. While cancer cells provide surface antigens that are targets for a desired immune response, they contain a high abundance of house-keeping proteins, carbohydrates, nucleic acids, and other intracellular contents that are ubiquitous in mammalian cells. These ubiquitous molecules are undesirable for targeting immune-based therapies. Another potential limitation with cell-based vaccines is the difficulty of purifying cells from possible dangerous intracellular contaminants such as cellular parasites, viruses, toxins and prions. Improving these aspects of cellbased vaccines is essential for improving the stringency and efficacy of cancer vaccines [3,4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
